Stargardt Disease Clinical Trial
Official title:
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD
This study evaluates the effects of orally-administered ALK-001 on the progression of Stargardt disease (ABCA4-related). Stargardt disease is a rare genetic disorder that leads to damage to the retina and results in legal blindness. Stargardt disease is caused by a defective ABCA4 gene, which affects the processing of vitamin A in the eye and leads to the formation of toxic vitamin A aggregates (called "vitamin A dimers") in the eye. Vitamin A dimers are thought to contribute to vision loss in Stargardt disease. ALK-001, the investigational drug, is a chemically-modified vitamin A designed as a replacement of vitamin A to prevent the formation of toxic vitamin A dimers in the eye. Trial participants will receive either ALK-001 or placebo, and follow-up visits will take place periodically for up to 24 months. There is currently no treatment for Stargardt disease. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01676766 -
Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease
|
N/A | |
| Enrolling by invitation |
NCT06048185 -
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
|
||
| Completed |
NCT03772665 -
Safety and Efficacy of Emixustat in Stargardt Disease
|
Phase 3 | |
| Recruiting |
NCT04545736 -
Oral Metformin for Treatment of ABCA4 Retinopathy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05674058 -
Function and Imaging Assessments for G1961E-associated Stargardt Disease
|
||
| Completed |
NCT04909398 -
Pupil Dynamics and Color Vision for the Detection of Eye Diseases
|
N/A | |
| Completed |
NCT02255981 -
Efficacy of Acupuncture in Macular Diseases
|
N/A | |
| Completed |
NCT05266014 -
This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02435940 -
Inherited Retinal Degenerative Disease Registry
|
||
| Completed |
NCT05417126 -
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
|
Phase 2 | |
| Terminated |
NCT02875704 -
Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy
|
||
| Completed |
NCT03033108 -
Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
|
Phase 2 | |
| Recruiting |
NCT03011541 -
Stem Cell Ophthalmology Treatment Study II
|
N/A | |
| Completed |
NCT02410122 -
The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy
|
||
| Enrolling by invitation |
NCT04239625 -
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
|
Phase 2 | |
| Recruiting |
NCT05956626 -
Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease
|
Phase 1/Phase 2 | |
| Completed |
NCT01977846 -
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
|
||
| Completed |
NCT05904444 -
The Effect of Duration Between Sessions on Microperimetric Biofeedback Training in Patients With Maculopathies
|
N/A | |
| Completed |
NCT02230228 -
Phase 1 Safety Study of ALK-001 in Healthy Volunteers
|
Phase 1 | |
| Not yet recruiting |
NCT06319872 -
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
|
Phase 1 |